Newly FDA-approved drugs for ovarian, bladder, liver cancer, and more.

Approved for CLL and SLL—types of leukemia and lymphoma—Brukinsa caused fewer heart-related side effects in trials.

Jaypirca (pirtobrutinib) is a highly selective kinase inhibitor that utilizes a novel binding mechanism.

Research at #ASH22 calls into question longstanding assumptions and charts a path for gentler therapies.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

The first two people treated with the “living drug” remained cancer-free for a decade and can be considered cured.